	US 12,220,465 B2
	Compositions and methods for targeted treatment and imaging of cancer or tumors
Abdel Kareem Azab, St. Louis, MO (US); and Barbara Muz, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by Washington University, St. Louis, MO (US)
Filed on Nov. 27, 2019, as Appl. No. 16/698,068.
Claims priority of provisional application 62/772,365, filed on Nov. 28, 2018.
Prior Publication US 2020/0179520 A1, Jun. 11, 2020
Int. Cl. A61K 47/46 (2006.01); A61K 51/04 (2006.01); A61K 51/12 (2006.01); C12N 5/071 (2010.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01)

CPC A61K 51/0491 (2013.01) [A61K 51/1244 (2013.01); C12N 5/0692 (2013.01); A61K 45/06 (2013.01); A61K 49/0017 (2013.01); C12N 2500/02 (2013.01); C12N 2502/30 (2013.01)]

7 Claims

1. A delivery system comprising a population of primed endothelial progenitor cells (EPCs) labeled with a photo- or radiation-activated anti-cancer prodrug, wherein the population of EPCs is obtained by culturing EPCs with a priming medium, wherein the priming medium is a cancer cell condition medium, or a hypoxic cancer cell conditioned medium, wherein the anti-cancer prodrug is Bortezomib, Titanocene, or 4-Borono-L-Phenylalanine.